XENON PHARMACEUTICALS INC. (XENE) /
The cash flow of XENON PHARMACEUTICALS INC. over the past 10 years
Chart XENON PHARMACEUTICALS INC.: operating cash flow, capital expenditures, free cash flow, fiscal 2016–2025 Open the chart →In fiscal 2025, the latest fiscal year on file, XENON PHARMACEUTICALS INC.'s operating cash flow was -$279.12M and its capital expenditures $799K, leaving free cash flow of -$279.92M. Free cash flow was below zero in all 10 years shown. It ranged from -$279.92M in fiscal 2025 to -$5.95M in fiscal 2019. Capital expenditures were highest in fiscal 2023, at $5.62M.
Year by year
| Fiscal year | Operating cash flow | Capital expenditures | Free cash flow* |
|---|---|---|---|
| 2025ended Dec 31, 2025 | -$279.12M | $799K | -$279.92M |
| 2024ended Dec 31, 2024 | -$181.39M | $3.08M | -$184.46M |
| 2023ended Dec 31, 2023 | -$151.11M | $5.62M | -$156.73M |
| 2022ended Dec 31, 2022 | -$101.03M | $2.89M | -$103.92M |
| 2021ended Dec 31, 2021 | -$69.5M | $2.05M | -$71.55M |
| 2020ended Dec 31, 2020 | -$48.12M | $2.64M | -$50.76M |
| 2019ended Dec 31, 2019 | -$4.71M | $1.24M | -$5.95M |
| 2018ended Dec 31, 2018 | -$34.72M | $507K | -$35.23M |
| 2017ended Dec 31, 2017 | -$28.73M | $315K | -$29.04M |
| 2016ended Dec 31, 2016 | -$19.57M | $279K | -$19.85M |
Fiscal years as XENON PHARMACEUTICALS INC. reports them. * Calculated by us from the company's filed figures; — no figure on file. From SEC filings, updated nightly. How each line is read.
More on XENON PHARMACEUTICALS INC.
- The revenue of XENON PHARMACEUTICALS INC.
- The profitability of XENON PHARMACEUTICALS INC.
- The debt of XENON PHARMACEUTICALS INC.
- All of XENON PHARMACEUTICALS INC.'s financials, charted
Companies of a similar size
- BOOTBoot Barn Holdings, Inc.
- SMGScotts Miracle-Gro Co
- IRTINDEPENDENCE REALTY TRUST, INC.
- PRIMPrimoris Services Corporation
- BATRAATLANTA BRAVES HOLDINGS, INC.
Not investment advice. This page shows what XENON PHARMACEUTICALS INC. filed with the SEC. Nothing here is a recommendation about any security. Check important figures against the company's own filings.